2019 |
Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H
Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Int J Cancer ;2019
PMID
Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A
Correction to: Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.
BMC Cancer ;19(1)57, 2019
PMID
2018 |
Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
BMC Cancer ;18(1)1045, 2018
PMID
Abu Khamidakh AE, Rodriguez-Martinez A, Kaarniranta K, Kallioniemi A, Skottman H, Hyttinen J, Juuti-Uusitalo K
Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage.
Biomed Eng Online ;17(1)102, 2018
PMID
Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A
Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.
BMC Cancer ;18(1)325, 2018
PMID
Ampuja M, Kallioniemi A
Transcription factors-Intricate players of the bone morphogenetic protein signaling pathway.
Genes Chromosomes Cancer ;57(1)3-11, 2018
PMID
2017 |
Kuittinen T, Rovio P, Staff S, Luukkaala T, Kallioniemi A, Grénman S, Laurila M, Mäenpää J
In Vitro.
Anticancer Res ;37(12)6575-6581, 2017
PMID
Mantere T, Tervasmäki A, Nurmi A, Rapakko K, Kauppila S, Tang J, Schleutker J, Kallioniemi A, Hartikainen JM, Mannermaa A, Nieminen P, Hanhisalo R, Lehto S, Suvanto M, Grip M, Jukkola-Vuorinen A, Tengström M, Auvinen P, Kvist A, Borg Å, Blomqvist C, Aittomäki K, Greenberg RA, Winqvist R, Nevanlinna H, Pylkäs K
Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.
Sci Rep ;7(1)681, 2017
PMID
Kiiski JI, Tervasmäki A, Pelttari LM, Khan S, Mantere T, Pylkäs K, Mannermaa A, Tengström M, Kvist A, Borg Å, Kosma VM, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Winqvist R, Nevanlinna H
FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
Breast Cancer Res Treat ;166(1)217-226, 2017
PMID
Määttä KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, Laasanen SL, Schleutker J
Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
BMC Cancer ;17(1)496, 2017
PMID
Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
J Pathol Clin Res ;3(2)123-138, 2017
PMID
Vuorinen EM, Rajala NK, Rauhala HE, Nurminen AT, Hytönen VP, Kallioniemi A
Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth.
Biochim Biophys Acta Mol Basis Dis ;1863(1)211-219, 2017
PMID
2016 |
Kiiski JI, Fagerholm R, Tervasmäki A, Pelttari LM, Khan S, Jamshidi M, Mantere T, Pylkäs K, Bartek J, Bartkova J, Mannermaa A, Tengström M, Kosma VM, Winqvist R, Kallioniemi A, Aittomäki K, Blomqvist C, Nevanlinna H
FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
Int J Cancer ;139(12)2760-2770, 2016
PMID
Alarmo EL, Havunen R, Häyrynen S, Penkki S, Ketolainen J, Nykter M, Kallioniemi A
Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion.
Genes Chromosomes Cancer ;55(3)227-36, 2016
PMID
2015 |
Juuti-Uusitalo K, Nieminen M, Treumer F, Ampuja M, Kallioniemi A, Klettner A, Skottman H
Effects of Cytokine Activation and Oxidative Stress on the Function of the Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells.
Invest Ophthalmol Vis Sci ;56(11)6265-74, 2015
PMID
2014 |
Wikman H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, Huhtala H, Terracciano L, Kallioniemi A, Sauter G, Müller V, Witzel I, Lamszus K, Kemming D, Pantel K
Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.
Oncotarget ;5(10)3076-87, 2014
PMID
Heikkinen T, Khan S, Huovari E, Vilske S, Schleutker J, Kallioniemi A, Blomqvist C, Aittomäki K, Nevanlinna H
Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families.
Breast Cancer Res Treat ;144(2)437-41, 2014
PMID
Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S, Kallioniemi A, Schleutker J, Leminen A, Bützow R, Blomqvist C, Barkardottir RB, Couch FJ, Aittomäki K, Nevanlinna H
Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Proc Natl Acad Sci U S A ;111(42)15172-7, 2014
PMID
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M
Breast-cancer risk in families with mutations in PALB2.
N Engl J Med ;371(6)497-506, 2014
PMID
Laurila E, Vuorinen E, Savinainen K, Rauhala H, Kallioniemi A
KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro.
Exp Cell Res ;322(1)159-67, 2014
PMID
2013 |
Laurila EM, Kallioniemi A
The diverse role of miR-31 in regulating cancer associated phenotypes.
Genes Chromosomes Cancer ;52(12)1103-13, 2013
PMID
Laurila R, Parkkila S, Isola J, Kallioniemi A, Alarmo EL
The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues.
Int J Clin Exp Pathol ;6(7)1400-8, 2013
PMID
Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L, Vessella RL, Auvinen A, Visakorpi T, Tammela TL, Schleutker J
HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
Cancer Epidemiol Biomarkers Prev ;22(3)452-60, 2013
PMID
Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A
BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment.
BMC Cancer ;2013
PMID
Rauhala HE, Teppo S, Niemelä S, Kallioniemi A
Silencing of the ARP2/3 complex disturbs pancreatic cancer cell migration.
Anticancer Res ;33(1)45-52, 2013
PMID
Alarmo EL, Huhtala H, Korhonen T, Pylkkänen L, Holli K, Kuukasjärvi T, Parkkila S, Kallioniemi A
Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development.
Mod Pathol ;26(1)10-21, 2013
PMID
2012 |
Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen LA, Leminen A, Heikkilä P, Blomqvist C, Bützow R, Aittomäki K, Nevanlinna H
A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
J Med Genet ;49(7)429-32, 2012
PMID
Kallioniemi A
Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior.
Cancer Genet ;205(6)267-77, 2012
PMID
Laurila EM, Sandström S, Rantanen LM, Autio R, Kallioniemi A
Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells.
Genes Chromosomes Cancer ;51(6)557-68, 2012
PMID
Pylkäs K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, Winqvist R
Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network.
PLoS Genet ;8(6)e1002734, 2012
PMID
Solyom S, Aressy B, Pylkäs K, Patterson-Fortin J, Hartikainen JM, Kallioniemi A, Kauppila S, Nikkilä J, Kosma VM, Mannermaa A, Greenberg RA, Winqvist R
Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions.
Sci Transl Med ;4(122)122ra23, 2012
PMID
Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.
Proc Natl Acad Sci U S A ;109(8)2736-41, 2012
PMID
2011 |
Virtanen S, Alarmo EL, Sandström S, Ampuja M, Kallioniemi A
Bone morphogenetic protein -4 and -5 in pancreatic cancer--novel bidirectional players.
Exp Cell Res ;317(15)2136-46, 2011
PMID
Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H
RAD51C is a susceptibility gene for ovarian cancer.
Hum Mol Genet ;20(16)3278-88, 2011
PMID
Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S
Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins.
PLoS One ;6(11)e27152, 2011
PMID
Kuuselo R, Savinainen K, Sandström S, Autio R, Kallioniemi A
MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.
Int J Cancer ;129(11)2553-65, 2011
PMID
Rodriguez-Martinez A, Alarmo EL, Saarinen L, Ketolainen J, Nousiainen K, Hautaniemi S, Kallioniemi A
Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes.
BMC Med Genomics ;2011
PMID
2010 |
Ketolainen JM, Alarmo EL, Tuominen VJ, Kallioniemi A
Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4.
Breast Cancer Res Treat ;124(2)377-86, 2010
PMID
Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, Yekebas E, Sauter G, Kallioniemi A
19q13 amplification is associated with high grade and stage in pancreatic cancer.
Genes Chromosomes Cancer ;49(6)569-75, 2010
PMID
Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H
Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
BMC Cancer ;2010
PMID
Alarmo EL, Kallioniemi A
Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?
Endocr Relat Cancer ;17(2)R123-39, 2010
PMID
Kallioniemi A
DNA copy number analysis on tissue microarrays.
Methods Mol Biol ;2010
PMID
2009 |
Laurila E, Savinainen K, Kuuselo R, Karhu R, Kallioniemi A
Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer.
Genes Chromosomes Cancer ;48(4)330-9, 2009
PMID
Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R, Kallioniemi A
BMP7 influences proliferation, migration, and invasion of breast cancer cells.
Cancer Lett ;275(1)35-43, 2009
PMID
2008 |
Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, Monni O
Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
BMC Genomics ;2008
PMID
Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
Nat Genet ;40(7)844-53, 2008
PMID
Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, Kallioniemi A, Meling GI, Skotheim RI, Rognum TO, Thiis-Evensen E, Lothe RA
Hypermethylated MAL gene - a silent marker of early colon tumorigenesis.
J Transl Med ;2008
PMID
Kallioniemi A
CGH microarrays and cancer.
Curr Opin Biotechnol ;19(1)36-40, 2008
PMID
Pärssinen J, Alarmo EL, Khan S, Karhu R, Vihinen M, Kallioniemi A
Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Cancer Lett ;259(1)61-70, 2008
PMID
Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL
Penetrance analysis of the PALB2 c.1592delT founder mutation.
Clin Cancer Res ;14(14)4667-71, 2008
PMID
Pärssinen J, Alarmo EL, Karhu R, Kallioniemi A
PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Cancer Genet Cytogenet ;182(1)33-9, 2008
PMID
2007 |
Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R
A recurrent mutation in PALB2 in Finnish cancer families.
Nature ;446(7133)316-9, 2007
PMID
Syrjäkoski K, Jäntti J, Kallioniemi A, Karhu R
Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer.
Int J Cancer ;120(2)444-6, 2007
PMID
Alarmo EL, Kuukasjärvi T, Karhu R, Kallioniemi A
A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.
Breast Cancer Res Treat ;103(2)239-46, 2007
PMID
Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.
Cancer Res ;67(5)1943-9, 2007
PMID
2006 |
Karhu R, Mahlamäki E, Kallioniemi A
Pancreatic adenocarcinoma -- genetic portrait from chromosomes to microarrays.
Genes Chromosomes Cancer ;45(8)721-30, 2006
PMID
Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A
Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer.
Genes Chromosomes Cancer ;45(4)411-9, 2006
PMID
Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Breast Cancer Res Treat ;95(3)257-63, 2006
PMID
Karhu R, Laurila E, Kallioniemi A, Syrjäkoski K
Large genomic BRCA2 rearrangements and male breast cancer.
Cancer Detect Prev ;30(6)530-4, 2006
PMID
2005 |
Honrado E, Osorio A, Palacios J, Milne RL, Sánchez L, Díez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkilä P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benítez J
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
J Clin Oncol ;23(30)7503-11, 2005
PMID
Laurila E, Syrjäkoski K, Holli K, Kallioniemi A, Karhu R
Search for large genomic alterations of the BRCA1 gene in a Finnish population.
Cancer Genet Cytogenet ;163(1)57-61, 2005
PMID
Wikman H, Nymark P, Väyrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, Vainio-Siukola K, Husgafvel-Pursiainen K, Knuutila S, Wolf M, Anttila S
CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer.
Genes Chromosomes Cancer ;42(2)193-9, 2005
PMID
2004 |
Bärlund M, Kuukasjärvi T, Syrjäkoski K, Auvinen A, Kallioniemi A
Frequent amplification and overexpression of CCND1 in male breast cancer.
Int J Cancer ;111(6)968-71, 2004
PMID
Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A, Kallioniemi A
Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines.
Oncogene ;23(4)1010-3, 2004
PMID
2003 |
Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Soeter G, Nesland JM, Smeland S, Kallioniemi OP, Lothe RA
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.
J Clin Oncol ;21(24)4586-91, 2003
PMID
Kauraniemi P, Kuukasjärvi T, Sauter G, Kallioniemi A
Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer.
Am J Pathol ;163(5)1979-84, 2003
PMID
Autio R, Hautaniemi S, Kauraniemi P, Yli-Harja O, Astola J, Wolf M, Kallioniemi A
CGH-Plotter: MATLAB toolbox for CGH-data analysis.
Bioinformatics ;19(13)1714-5, 2003
PMID
Kallioniemi A
[Gene expression profile as a crystal ball].
Duodecim ;119(12)1101-2, 2003
PMID
2002 |
Andersen CL, Monni O, Wagner U, Kononen J, Bärlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A
High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays.
Am J Pathol ;161(1)73-9, 2002
PMID
Kallioniemi A
Molecular signatures of breast cancer--predicting the future.
N Engl J Med ;347(25)2067-8, 2002
PMID
Mahlamäki EH, Bärlund M, Tanner M, Gorunova L, Höglund M, Karhu R, Kallioniemi A
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer.
Genes Chromosomes Cancer ;35(4)353-8, 2002
PMID
Bärlund M, Monni O, Weaver JD, Kauraniemi P, Sauter G, Heiskanen M, Kallioniemi OP, Kallioniemi A
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer.
Genes Chromosomes Cancer ;35(4)311-7, 2002
PMID
Skotheim RI, Monni O, Mousses S, Fosså SD, Kallioniemi OP, Lothe RA, Kallioniemi A
New insights into testicular germ cell tumorigenesis from gene expression profiling.
Cancer Res ;62(8)2359-64, 2002
PMID
Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringnér M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP, Kallioniemi A
Impact of DNA amplification on gene expression patterns in breast cancer.
Cancer Res ;62(21)6240-5, 2002
PMID
Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Appella E
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Nat Genet ;31(2)210-5, 2002
PMID
Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, Moskaluk C, Frierson H, Powell SM, Knuutila S, Kallioniemi A, El-Rifai W
Targets of gene amplification and overexpression at 17q in gastric cancer.
Cancer Res ;62(9)2625-9, 2002
PMID
Mousses S, Kallioniemi A, Kauraniemi P, Elkahloun A, Kallioniemi OP
Clinical and functional target validation using tissue and cell microarrays.
Curr Opin Chem Biol ;6(1)97-101, 2002
PMID
2001 |
Kauraniemi P, Bärlund M, Monni O, Kallioniemi A
New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Cancer Res ;61(22)8235-40, 2001
PMID
Monni O, Hyman E, Mousses S, Barlund M, Kallioniemi A, Kallioniemi OP
From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome.
Semin Cancer Biol ;11(5)395-401, 2001
PMID
Andersen CL, Hostetter G, Grigoryan A, Sauter G, Kallioniemi A
Improved procedure for fluorescence in situ hybridization on tissue microarrays.
Cytometry ;45(2)83-6, 2001
PMID
Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML, Kallioniemi A
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer.
Proc Natl Acad Sci U S A ;98(10)5711-6, 2001
PMID
Heiskanen M, Kononen J, Bärlund M, Torhorst J, Sauter G, Kallioniemi A, Kallioniemi O
CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors.
Anal Cell Pathol ;22(4)229-34, 2001
PMID
2000 |
Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S
Novel findings in gene expression detected in human osteosarcoma by cDNA microarray.
Cancer Genet Cytogenet ;123(2)128-32, 2000
PMID
Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi A
Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.
J Natl Cancer Inst ;92(15)1252-9, 2000
PMID
Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res ;60(16)4519-25, 2000
PMID
1999 |
Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP
Molecular cytogenetic analysis of 11 new breast cancer cell lines.
Br J Cancer ;81(8)1328-34, 1999
PMID
Paavola P, Avela K, Horelli-Kuitunen N, Bärlund M, Kallioniemi A, Idänheimo N, Kyttälä M, de la Chapelle A, Palotie A, Lehesjoki AE, Peltonen L
High-resolution physical and genetic mapping of the critical region for Meckel syndrome and Mulibrey Nanism on chromosome 17q22-q23.
Genome Res ;9(3)267-76, 1999
PMID
Vidgren V, Varis A, Kokkola A, Monni O, Puolakkainen P, Nordling S, Forozan F, Kallioniemi A, Vakkari ML, Kivilaakso E, Knuutila S
Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer.
Genes Chromosomes Cancer ;24(1)24-9, 1999
PMID
1998 |
Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP
Tissue microarrays for high-throughput molecular profiling of tumor specimens.
Nat Med ;4(7)844-7, 1998
PMID
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP
Molecular cytogenetics of primary breast cancer by CGH.
Genes Chromosomes Cancer ;21(3)177-84, 1998
PMID
Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.
Cancer Genet Cytogenet ;101(1)53-7, 1998
PMID
Bärlund M, Nupponen NN, Karhu R, Tanner MM, Paavola P, Kallioniemi OP, Kallioniemi A
Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17.
Cytogenet Cell Genet ;82(3-4)189-91, 1998
PMID
1997 |
Forozan F, Karhu R, Kononen J, Kallioniemi A, Kallioniemi OP
Genome screening by comparative genomic hybridization.
Trends Genet ;13(10)405-9, 1997
PMID
Bärlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A
Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions.
Genes Chromosomes Cancer ;20(4)372-6, 1997
PMID
Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Weidner N, Waldman FM
Genetic alterations in lobular breast cancer by comparative genomic hybridization.
Int J Cancer ;74(5)513-7, 1997
PMID
Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.
Cancer Res ;57(8)1597-604, 1997
PMID
1996 |
Tanner MM, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjärvi T, Collins C, Kowbel D, Guan XY, Trent J, Gray JW, Meltzer P, Kallioniemi OP
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer.
Cancer Res ;56(15)3441-5, 1996
PMID
Kallioniemi A, Visakorpi T, Karhu R, Pinkel D, Kallioniemi OP
Gene Copy Number Analysis by Fluorescence in Situ Hybridization and Comparative Genomic Hybridization
Methods ;9(1)113-21, 1996
PMID
Deng G, Yu M, Chen LC, Moore D, Kurisu W, Kallioniemi A, Waldman FM, Collins C, Smith HS
Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction.
Breast Cancer Res Treat ;40(3)271-81, 1996
PMID
1995 |
Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW, Kallioniemi OP, Isola J
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications.
Clin Cancer Res ;1(12)1455-61, 1995
PMID
Bryndorf T, Kirchhoff M, Rose H, Maahr J, Gerdes T, Karhu R, Kallioniemi A, Christensen B, Lundsteen C, Philip J
Comparative genomic hybridization in clinical cytogenetics.
Am J Hum Genet ;57(5)1211-20, 1995
PMID
Sauter G, Carroll P, Moch H, Kallioniemi A, Kerschmann R, Narayan P, Mihatsch MJ, Waldman FM
c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.
Am J Pathol ;146(5)1131-9, 1995
PMID
Stokke T, Collins C, Kuo WL, Kowbel D, Shadravan F, Tanner M, Kallioniemi A, Kallioniemi OP, Pinkel D, Deaven L
A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis.
Genomics ;26(1)134-7, 1995
PMID
Kallioniemi A, Kallioniemi OP, Citro G, Sauter G, DeVries S, Kerschmann R, Caroll P, Waldman F
Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization.
Genes Chromosomes Cancer ;12(3)213-9, 1995
PMID
Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP
Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.
Cancer Res ;55(2)342-7, 1995
PMID
Piper J, Rutovitz D, Sudar D, Kallioniemi A, Kallioniemi OP, Waldman FM, Gray JW, Pinkel D
Computer image analysis of comparative genomic hybridization.
Cytometry ;19(1)10-26, 1995
PMID
Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Böhling T, Karaharju E, Hyytinen E, Knuutila S
Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization.
Cancer Res ;55(6)1334-8, 1995
PMID
1994 |
Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors.
Genes Chromosomes Cancer ;10(4)231-43, 1994
PMID
Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization.
Am J Pathol ;145(3)624-30, 1994
PMID
Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo WL
Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes.
Cancer Res ;54(16)4257-60, 1994
PMID
Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi OP, Isola JJ
Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization.
Cytometry ;16(2)93-9, 1994
PMID
Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.
Proc Natl Acad Sci U S A ;91(6)2156-60, 1994
PMID
Kallioniemi OP, Kallioniemi A, Mascio L, Sudar D, Pinkel D, Deaven L, Gray J
Physical mapping of chromosome 17 cosmids by fluorescence in situ hybridization and digital image analysis.
Genomics ;20(1)125-8, 1994
PMID
Gray JW, Collins C, Henderson IC, Isola J, Kallioniemi A, Kallioniemi OP, Nakamura H, Pinkel D, Stokke T, Tanner M
Molecular cytogenetics of human breast cancer.
Cold Spring Harb Symp Quant Biol ;1994
PMID
1993 |
Mohamed AN, Macoska JA, Kallioniemi A, Kallioniemi OP, Waldman F, Ratanatharathorn V, Wolman SR
Extrachromosomal gene amplification in acute myeloid leukemia; characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR.
Genes Chromosomes Cancer ;8(3)185-9, 1993
PMID
Kallioniemi OP, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D
Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors.
Semin Cancer Biol ;4(1)41-6, 1993
PMID
1992 |
Gray JW, Kallioniemi A, Kallioniemi O, Pallavicini M, Waldman F, Pinkel D
Molecular cytogenetics: diagnosis and prognostic assessment.
Curr Opin Biotechnol ;3(6)623-31, 1992
PMID
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.
Science ;258(5083)818-21, 1992
PMID
Kallioniemi A, Kallioniemi OP, Waldman FM, Chen LC, Yu LC, Fung YK, Smith HS, Pinkel D, Gray JW
Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization.
Cytogenet Cell Genet ;60(3-4)190-3, 1992
PMID
Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
Proc Natl Acad Sci U S A ;89(12)5321-5, 1992
PMID
Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Pinkel D, Gray J, Waldman FM
Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization.
Cancer Res ;52(12)3474-7, 1992
PMID
1991 |
Gray JW, Lucas J, Kallioniemi O, Kallioniemi A, Kuo WL, Straume T, Tkachuk D, Tenjin T, Weier HU, Pinkel D
Applications of fluorescence in situ hybridization in biological dosimetry and detection of disease-specific chromosome aberrations.
Prog Clin Biol Res ;1991
PMID
1990 |
Ojala A, Kallioniemi OP, Wigren T, Kallioniemi A, Mattila J, Lehtinen M, Koivula T
Flow cytometric analysis of tumour DNA profile related to response to radiotherapy and survival in inoperable lung cancer.
Acta Oncol ;29(8)983-8, 1990
PMID
